Literature DB >> 23351469

[Role of echocardiography in suspected pulmonary hypertension].

Francisco Javier Guerra Ramos1.   

Abstract

Echocardiography is the non-invasive method of choice for the study of patients with suspected pulmonary hypertension. This technique allows systolic pulmonary artery pressure to be estimated and can also provide additional information on the cause and effects of the disease. To estimate systolic pulmonary pressure, equivalent to right ventricular systolic pressure, maximal flow velocity of tricuspid regurgitation and right atrial pressure--estimated on the basis of the degree of inferior vena cava dilation--can be employed. Other parameters that should be evaluated are those related to right cavity size and right ventricular function. Unlike the left ventricle, the anatomy and geometry of the right ventricle is complex, hampering calculation of its systolic function. Consequently, over the years, various indirect methods have been developed to estimate right systolic function, the most commonly used being tricuspid annular plane systolic excursion (TAPSE) and the Tei index. New echocardiographic methods such as study of myocardial deformation (strain) and three-dimensional echocardiography may soon provide data suggesting poor clinical course in the short and medium term. Consequently, accurate determination and characterization of these data are essential.
Copyright © 2011 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 23351469     DOI: 10.1016/S0300-2896(11)70053-9

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  1 in total

1.  Prediction of Early Postoperative Major Cardiac Events and In-Hospital Mortality in Elderly Hip Fracture Patients: The Role of Different Types of Preoperative Cardiac Abnormalities on Echocardiography Report.

Authors:  Xuepan Chen; Yuanchen Ma; Zhantao Deng; Qingtian Li; JunXing Liao; Qiujian Zheng
Journal:  Clin Interv Aging       Date:  2020-05-27       Impact factor: 4.458

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.